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Suppression of p21 has been implicated in the genesis and progression of many human malignancies.  
DNA methylation is an important mechanism of gene silencing in human malignancies.  In this study,  
we examined the expression status and aberrant methylaion of p21 in lung cancers and malignant 
pleural mesotheliomas (MPM).  We used 12 small cell lung cancer (SCLC) cell lines,  13 non-small cell 
lung cancer (NSCLC) cell lines,  50 primary NSCLCs,  6 MPM cell lines and 10 primary MPMs.  The 
expression and methylation of p21 was examined by reverse transcription-PCR (RT-PCR),  Western 
blotting and methylation-speciﬁc PCR (MSP) assay.  Loss of p21 protein expression was observed in 7 
SCLC cell lines (58.3ｵ),  5 NSCLC cell lines (38.5ｵ) and 3 MPM cell lines (50ｵ) while mRNA expression 
was lost in 2 SCLC cell lines (16.7ｵ),  2 NSCLC cell lines (15.4ｵ) and none of the MPM cell lines.  
Aberrant methylation of p21 was found in 8.3ｵ of SCLC cell lines,  30.2ｵ of NSCLCs and 6.3ｵ of 
MPMs.  Among primary NSCLCs,  methylation in adenocarcinomas was signiﬁcantly more frequent 
than in squamous cell carcinomas.  Loss of p21 expression was frequently observed in lung cancers and 
MPMs and aberrant methylation was one of the mechanisms of suppression of p21,  especially in 
NSCLCs.
Key words: p21,  methylation,  lung cancer,  mesothelioma
he cell cycle progresses through sequential 
activation and inactivation of cyclin-dependent 
kinases (CDKs).  The transition from the G1 to the S 
phase is known to be regulated by a family of negative 
cell cycle regulators known as,  CDK inhibitors.  p21 
(CDKN1A/CIP1/WAF1) is one of the CDK inhibi-
tors and plays a key role in preventing the progression 
to the S phase of the cell cycle [1,  2].  p21 has been 
shown to have a pro-apoptotic role under p53-medi-
ated apoptosis and to be activated by p53,  which was 
shown to be a tumor suppressor gene and to have been 
inactivated in several human malignancies.
　 Recently,  epigenetic alterations including promoter 
DNA methylation and histone deacetylation have been 
established as one of the crucial mechanisms of car-
cinogenesis.  Among them,  transcriptional inactivation 
by promoter methylation in various tumor suppressor 
genes plays an important role in human malignancies 
including lung cancers and malignant pleural mesothe-
liomas (MPMs) [3,  4].  Loss of p21 has been shown 
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to occur in colorectal cancer,  but promoter methyla-
tion does not appear to play a key role in the loss of 
function [5].  Additionally,  the p21 gene is frequently 
methylated and is an important factor in predicting the 
clinical outcome of acute lymphoblastic leukemia 
patients [6,  7].  On the other hand,  almost no muta-
tion in the p21 gene has been found in malignancies 
[8].
　 Several tumor suppressor genes are silenced by 
promoter methylation in lung cancers and MPM,  but 
the subsets of genes that are aﬀected by methylation 
in these 2 kinds of malignancies are quite diﬀerent 
[4].  In lung cancers,  the proﬁle of gene methylation 
is aﬀected by clinicopathological features such as 
smoking status and histological subtype [3].  Low 
frequency of p21 methylation was previously reported 
in a study that examined a small number of lung cancer 
cell lines [9].  However,  no information of regarding 
primary tumors has been documented.  In addition,  no 
study has shown p21 methylation in MPMs.  In this 
study,  we examined the DNA methylation of the p21 
gene in lung cancers and MPMs and assessed the 
extent to which it correlated with the expression of 
p21 as well as that of p53.  We also investigated the 
relationship between p21 methylation and the clinico-
pathological features of primary lung cancers.
Materials and Methods
　 Clinical samples and cell lines. Twelve 
SCLC,  13 NSCLC and 6 MPM cell lines were used 
in this study.  The HP1 cell line was a kind gift from 
Dr. Harvey I. Pass; the SBC-3,  SBC-4 and SBC-5 
cell lines were from Dr. Katsuyuki Kiura (Okayama 
University) and other cell lines were from Dr. Adi F. 
Gazdar (University of Texas Southwestern Medical 
Center,  Dallas,  TX,  USA).  The human bronchial 
epithelial cell (HBEC) 5KT cell established from non-
malignant human bronchial cells was also provided by 
Dr. Adi F. Gazdar.  The cells were maintained in 
RPMI-1640 medium (Sigma Chemical Co.,  Saint 
Louis,  MO,  USA) supplemented with 10ｵ FBS and 
incubated in 5ｵ CO2.  Surgically resected specimens 
of 50 NSCLCs were obtained from Okayama 
University Hospital,  and 10 MPMs were obtained 
from Karmanos Cancer Center,  Detroit,  MI,  USA.  
Ten non-neoplastic pleura and 10 non-malignant lung 
tissues from lung cancer patients were obtained from 
surgically resected pulmonary specimens and used for 
the methylation assay.  All tissues were frozen with 
liquid nitrogen immediately after surgery and stored 
at －80℃ after the acquisition of informed consent 
from each patient.
　Western blot analysis. Cells were grown to 
80ｵ conﬂuency and harvested in lysis buﬀer 
[20mmol/L Tris-HCl (pH7.5),  150mmol/L NaCl,  
1mmol/L Na2EDTA,  1mmol/L EGTA,  1ｵ Triton,  
2.5mmol/L sodium pyrophosphate,  1mmol/L beta-
glycerophosphate,  1mmol/L Na3VO4,  1µg/ml leu-
peptin] (Cell Signaling Technology,  Beverly,  MA,  
USA) supplemented with Complete,  Mini (Roche,  
Basel,  Switzerland) to extract protein.  A total 30µg 
of protein was separated by SDS-PAGE and trans-
ferred to PVDF membranes.  The proteins on mem-
branes were incubated overnight at 4℃ with the pri-
mary antibodies.  The primary antibodies of anti-p21 
and anti-p53 (Cat-No.  #2946 and #9282; Cell 
Signaling Technology,  Danvers,  MA,  USA) were 
used for Western blotting.  The following secondary 
antibodies were used: goat antirabbit or antimouse 
IgG-conjugated horseradish peroxidase (HRP) (Santa 
Cruz,  CA,  USA).  To detect speciﬁc signals,  the 
membranes were detected by ECL plus Western 
Blotting Detection Reagents (Amersham Biosciences 
UK Limited,  Buckinghamshire,  UK).
　 Expression of p21 mRNA. Total cellular 
RNA was isolated from cell lines using an RNeasy 
minikit (Qiagen Sciences,  Maryland) according to the 
manufacturerʼs instructions and then treated with 
2units/µL of DNase I (Ambion,  Austin,  TX,  USA) 
for 30min at 37℃.  RT reaction was performed for 
2µg of total RNA with the SuperScript II First-
strand Synthesis using the Oligo (dT) primer system 
(Invitrogen Life Technologies,  Inc.,  Carlsbad,  CA,  
USA) in 20µl of reaction mixture.  Expression of p21 
was conﬁrmed by RT-PCR.  The primers designed by 
primer 3 targeting p21 cDNA were as follows (sense 
and antisense,  respectively): 5ʼ-GCTCTGCTGCA-
GGGGACAGC-3ʼ,  and 5ʼ-TCTGCCGCCGTTTTCG-
ACCC-3ʼ.  GAPDH was used as a control.  The 25-µl 
reaction mixtures contained the forward and reverse 
primers at 300nM each,  1 unit of HotStar Taq DNA 
polymerase (Qiagen Science) and 5µl cDNA from the 
20-µl volume of RT reaction mixture.  PCR was per-
formed under the following conditions: 50℃ for 2min 
and 95℃ for 10min,  followed by 40 cycles of 95℃ 
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for 15sec and 60℃ for 1min.  RT-PCR products 
were analyzed in 2ｵ agarose gels and stained with 
ethidium bromide.
　 5-aza-2ʼ-deoxycytidine treatment. Two cell 
lines,  H522 and H841,  were treated with 5-aza-2ʼ-
deoxycytidine (Sigma-Aldrich Co.) at a concentration 
of 5µM for 6 days to restore gene expression.
　 Methylation speciﬁc PCR (MSP) assay and 
bisulfate DNA sequencing. Genomic DNA was 
extracted from cell lines and tissues by standard phe-
nol-chloroform (1 : 1) extraction or using a DNeasy 
Tissue Kit (QIAGEN,  Valencia,  CA,  USA).  DNA 
was subjected to bisulfate treatment using the EZ 
DNA Methylation Gold kit (Zymo Research Corp.,  
Orange,  CA,  USA) according to the manufacturerʼs 
protocol.  The methylation statuses of p21 were deter-
mined by MSP assay using speciﬁc primers for the 
methylated and unmethylated forms in accordance with 
a previous report [10].  The DNA from HBEC 5KT 
was treated with Sss1 methyltransferase (New 
England BioLabs,  Beverly,  MA,  USA) and was used 
as a positive control for methylated alleles.  PCR 
products were analyzed in 2ｵ agarose gels and 
stained with ethidium bromide.
　 Statistics. Univariate analysis of the methyla-
tion rate was carried out using the χ2 test and multi-
variate analysis was done using multiple logistic 
regression analysis.  All data were analyzed with JMP 
for Windows (SAS Institute,  Tokyo,  Japan).
Results
　 The expression of p21 in cell lines was examined 
using RT-PCR and Western blotting (Fig.  1).  The 
expression of the p53 protein as determined by 
Western blotting and the genetic alteration of p53 
status which has been reported in databases of Trust 
Sanger Institute (www.sanger.ac.uk) are shown in 
Table 1.  The p53 expression was preserved in 7 
SCLC cell lines (58.3ｵ),  7 NSCLC cell lines 
(53.8ｵ) and 5 MPM cell lines (83.3ｵ).  The loss of 
p21 mRNA expression was observed in 2 SCLC cell 
lines (16.7ｵ),  2 NSCLC cell lines (15.4ｵ) and none 
of the MPM cell lines (0ｵ),  while a loss of protein 
expression was observed in 7 SCLC cell lines 
(58.3ｵ),  5 NSCLC cell lines (38.5ｵ) and 3 MPM 
cell lines (50.0ｵ).  In 3 cell lines namely SBC-4,  
H358 and H1299,  negative p53 expression but positive 
p21 expression were shown,  which conﬂicted with the 
fact that p21 was mediated by p53.  However,  p21 
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Fig. 1　 Representative examples of the expression and methylation status of p21.  The upper panel shows the protein expression of p53 
and p21 protein.  Actin is used as a control.  The middle panel shows the mRNA expression of p21.  GAPDH is used as an expression 
control.  The lower panel shows the methylation status of the p21 gene.  HBEC cells are used as a normal control.  MSP,  
methylated; USP,  unmethylated.
expression was very weak in these cells.
　 A conventional MSP assay was performed,  and 
representative examples are shown.  Aberrant methy-
lation of p21 was found in 1 [H841] out of 12 (8.3ｵ) 
SCLC cell lines and 4 [H522,  H838,  H1299 and 
H1975] out of 13 (30.8ｵ) NSCLC cell lines.  All 5 
cell lines with aberrant methylation showed both 
methylated and unmethylated alleles,  which meant that 
the promoter of p21 was partially methylated.  Though 
H522,  H838 and H841 lost both p21 mRNA and pro-
tein,  the other 2 methylated cell lines retained the 
expression of p21.
　 Next,  we tested for aberrant methylaton of p21 in 
10 primary MPMs and 50 NSCLCs,  which included 
20 squamous cell carcinomas,  20 adenocarcinomas and 
10 adenocarcinomas with bronchioalveolar carcinoma 
features (BAC).  The methylation of p21 was found in 
13 (26ｵ) primary NSCLCs and only 1 (10ｵ) pri-
mary MPM (Fig.  2 and Table 2).  No methylation was 
found in non-malignant lung tissues,  non-neoplastic 
pleura specimens or non-malignant mesothelial cells.  
Among primary NSCLCs,  methylation in adenocarci-
nomas was signiﬁcantly more frequent than in 
squamous cell carcinomas (p＝0.03),  but there was no 
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Table 1　 Expression and methylation proﬁles of cell lines
Cell line Histology
p21 p53
Gene methy. mRNA exp. Protein exp. Gene mut. Protein exp.
H82 SCLC U ＋ － Splice mutation －
H211 SCLC U － － P248E ＋
H249 SCLC U ＋ － Wt ＋
H524 SCLC U ＋ － T155N ＋
H841 SCLC M/U － － C242S ＋
H1084 SCLC U ＋ ＋ S46F, R273C ＋
H1780 SCLC U ＋ ＋ ＊ ＋
H1963 SCLC U ＋ ＋ V147D, H214R ND
H2141 SCLC U ＋ － R209Stop －
SBC-3 SCLC U ＋ ＋ Wt ＋
SBC-4 SCLC U ＋ ＋ ＊ －
SBC-5 SCLC U ＋ － R245L －
A549 NSCLC (AD) U ＋ ＋ Wt ＋
H125 NSCLC (ADSQ) U ＋ － 239 frame shift －
H358 NSCLC (AD) U ＋ ＋ HD －
H460 NSCLC (LC) U ＋ ＋ Wt ＋
H522 NSCLC (AD) M/U － － 191 frame shift －
H661 NSCLC (LC) U ＋ － S215I ＋
H838 NSCLC (AD) M/U － － E62stop －
H1299 NSCLC (LC) M/U ＋ ＋ HD －
H1395 NSCLC (AD) U ＋ ＋ Wt ＋
H1975 NSCLC (AD) M/U ＋ ＋ R273H ＋
H3255 NSCLC(AD) U ＋ ＋ ＊ ND
HCC827 NSCLC (AD) U ＋ － ＊ ＋
PC-9 NSCLC (AD) U ＋ ＋ R24Q ＋
H28 MPM U ＋ ＋ ＊ ＋
H290 MPM U ＋ － ＊ ＋
H513 MPM U ＋ － ＊ －
H2052 MPM U ＋ ＋ ＊ ＋
H2452 MPM U ＋ ＋ ＊ ＋
HP1 MPM U ＋ － ＊ ＋
＊ There is no information about p53 gene mutation.
Wt,  wild type; HD,  homozygous deletion; ND,  not determined; U,  unmethylated; M,  methylated; M/U,  both methylated and unmethy-
lated alleles were present indicating partial methylation.  AD,  adenocarcinoma; ADSQ,  adenosquamous cell carcinoma; LC,  large cell 
carcinoma.
correlation between p21 methylation and smoking his-
tory or other characteristics (Table 2).
　 Two methylated cell lines,  H522 and H841,  were 
treated with 5-aza-2ʼ-deoxycytidine and p21 protein 
and mRNA expression was restored,  which indicated 
that methylation was responsible for p21 silencing 
(Fig.  3).
Discussion
　 In the present study,  we demonstrated that epige-
netic modiﬁcation of p21 via hypermethylation repre-
sents a critical mechanism for inactivation in lung 
cancers.  A previous report showed the hypermethyla-
tion of p21 using the digestion of CG-containing 
enzymes after bisulfate modiﬁcation in 4 out of 13 
lung cancer cell lines [9].  Though the methods were 
diﬀerent,  the frequency of p21 methylation observed 
in thas study is similar to our result.  However,  the 
hypermethylation of p21 was not the main mechanism 
of p21 suppression.  As we have shown in this study,  
a loss of p21 protein expression was frequently 
observed in lung cancer cell lines and MPM cell lines,  
while DNA methylation was observed to be less fre-
quent and partial in both lung cancer and MPM.  We 
showed the presence of methylation in primary tumors,  
and the frequency of methylation varied by histology.  
The suppression of p21 in MPMs was shown by immu-
nohistochemistry in a previous report [11].  We 
showed loss of p21 protein expression by Western 
blotting in 3 cell lines,  but DNA methylation was not 
the mechanism of this loss.
　 Most cell lines which lost p53 expression also lost 
p21 expression,  and even in cells in which p53 
expression was preserved,  the p53 mutation may ruin 
its transcriptional potency and cause p21 expression 
to be lost.  Additionally,  discrepancies between mRNA 
and protein expression were seen in 8 cell lines,  which 
may indicate a diﬀerence of sensitivity between PCR 
and blotting or the possibility of post-transcriptional 
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Fig. 2　 Representative results of MSP in primary tumors.  MSP,  
methylated; USP,  unmethylated; PC,  positive control.
Table 2A　 Frequency of DNA methylation of p21
Histology Sample kinds Number Methylated %
SCLC Cell line 12 1 8.3
NSCLC Cell line 13 4 30.8
Primary SQ 20 1 5 
Ad 20 9 45
BAC 10 3 30
MPM Cell line  6 0 0
Primary 10 1 10
Ad,  adenocarcinoma; SQ,  squamous cell carcinoma; BAC,  ade-
nocarcinomas with bronchioalveolar carcinoma features
Table 2B　 Patient characteristics and frequency of DNA methy-
lation in primary NSCLCs
Variables Number Methylated %
Age (year-old)
　　　＜70 27  8 30
　　　70ｦ 23  5 22
Gender
　　　Male 29  7 24
　　　Female 21  6 29
Smoking history
　　　Never smoker 17  7 41
　　　Ever smoker 33  6 18
Stage
　　　IA 32 11 34
　　　IB 11  0  0
　　　II, III  7  2 29
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Fig. 3　 Protein and mRNA expression after 5-Aza treatment in 
methylated cell lines.
modiﬁcation.  The mechanisms of p21 suppression vary 
in each cell line.  Still,  DNA methylation is a part of 
the mechanisms,  especially in NSCLCs.
　 The ARF/p53/p21 tumor suppression pathway acts 
as a molecular sensor and regulator of cellular stress,  
senescence,  and immortalization [12].  The p21 pro-
moter contains ﬁve p53 binding sites,  and its expres-
sion is regulated in manners both dependent and inde-
pendent of p53.  The p53-dependent induction of p21 
causes cell cycle arrest after DNA damage.  Also,  p21 
can be regulated independently from p53 in several 
situations including cellular diﬀerentiation and normal 
tissue development.  The fact that a basal level of p21 
can be found in some p53-null cell lines suggests that 
p21 can also be induced by pathways independent of 
p53.  Understanding the molecular regulation of this 
pathway by intrinsic and extrinsic signals is extremely 
important in order to address unsolved questions 
regarding senescence and cancer.  In tumor cells,  in 
the case of the loss of the p53 protein or the presence 
of an altered form of p53,  p21 expression is dramati-
cally reduced or totally absent.  Additionally,  the 
deletion and methylation of p21 itself,  have been 
shown in several malignancies.  The expression of p21 
has been reported as a prognostic factor in malignan-
cies.  The high expression of p21 was reported to be 
an independent prognostic factor associated with lon-
ger survival in NSCLC patients,  but some reports 
have shown a controversial result [13,  14].  A reduc-
tion of p21 expression has been reported to have sig-
niﬁcant positive relationship with poor survival in 
MPM patients [11].  Moreover,  SV40 protein which 
can inactivate p53,  may be involved in the silencing of 
p21 in MPMs.
　 In conclusion,  our results show that a loss of p21 
expression was frequently observed in lung cancers and 
MPMs and that aberrant methylation was one of the 
mechanisms by which p21 was suppressed,  especially 
in lung adenocaricnomas.
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